A new weight-loss pill taken daily could compete with injections like Ozempic, new research suggests. Patients, who all were ...

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in US trade ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Most U.S. stocks climbed Thursday, but the worst drop for UnitedHealth Group in a quarter of a century on the Dow Jones kept Wall Street in check.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Traders leaned toward optimism following Donald Trump’s comments about “big progress” in the bilateral talks after the ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...